Healthcare

Prescient Therapeutics Limited (ASX:PTX)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 0.250.015 (6.383%)

(as on 2021-10-24 09:56:05)

Market Cap : AUD 161.148 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.235 0.24 0.25 0.24L 0.25 H 0.054L 0.305 H
Last Trade 0.25
Change% 6.3830
52 W H/L 0.305/0.054
EBITDA -4.138 M
NPAT After Abnormal Items -4.149 M
Equity 20.427 M
ROE% -20.31%
Total Liabilities 539,677
Total Revenue 1.235 M
Cash and Cash Equivalents 16.098 M

Stock Information

Share price 0.25
Market Cap 161.148 M
Price/Gross Cash Flow -53.37
Dividend Yield Excluding Special 0.00%
Ending Shares 641.053 M
52-Week Range 0.054-0.305
P/E ratio 0.000
Sector P/E --
EPS -0.68
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.00
Net Gearing -77.99%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.03
Sales Per Share 0.00
Book Value Per Share 0.03

Announcements

Heading Date/Time

Similar Companies

Related Articles

Load More

About Company

ASX-listed clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) is focused on the development of revolutionary personalised therapies for challenging cancers having unmet medical need. Prescient’s key programs are universal CAR-T and targeted therapies. Both approaches seek to improve patient outcomes and develop new tools for clinicians to combat cancer.

Notably, Prescient Therapeutics is backed by a leading team of global cancer specialists who hold extensive experience in advancing new cancer therapies.

Prescient has a comprehensive product pipeline of personalised cancer treatments for several different cancers:

Source: PTX Website

CAR-T therapies include OmniCAR and Cell Therapy Enhancement Programs

OmniCAR program: Prescient’s universal CAR-T platform, OmniCAR, employs technology that is licensed from the University of Pennsylvania and Oxford University.

PTX’s pioneering OmniCAR program will allow unprecedented control and flexibility over the current generation CAR-T methods.

Interestingly, Prescient has announced three next-generation OmniCAR programs for AML, Her2+ solid tumours and glioblastoma multiforme (GBM). PTX has also entered into a new research agreement with Peter MacCallum Cancer Centre to advance its CAR-T programs.

Cell Therapy Enhancements (CTE): Prescient’s CTE programs are progressing well with initial promising findings. Two CTE programs are underway with Peter MacCallum and Carina Biotech, respectively.

Targeted Therapies - PTX-100 and PTX-200  

PTX-100 is a first in class RhoA inhibitor and can block GGT-1 (geranylgeranyl transferase-1), a crucial cancer growth enzyme.

  • Currently, the compound is in a PK/PD basket study to treat hematological and solid cancers, focusing on malignancies with Ras and RhoA mutations.
  • In an earlier Phase 1 trial for advanced solid tumours, PTX-100 achieved stable disease and was well tolerated.

PTX-200, a novel PH domain inhibitor, blocks Akt pathway. Akt plays a vital role in the development of numerous malignancies, including breast and ovarian cancer and leukemia.  

  • PTX-200 has a unique mechanism of particularly inhibiting the Akt pathway in a comparatively safe manner, unlike other drugs targeting Akt inhibition.
  • PTX-200 has previously reported promising data in Phase 2a study for HER2-negative breast cancer and Phase 1b trial in ovarian cancer (recurrent or persistent platinum-resistant).
  • Currently, Prescient is assessing PTX-200 in relapsed and refractory Acute Myeloid Leukemia.

Corporate Information

company address Level 4, 100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA, 3205

company phone(03) 9692 7222

company email[email protected]

company websitehttps://ptxtherapeutics.com/

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-08-29 2022
Report (Prelim) 2022-08-29 2022
Report (Interim) 2022-02-23 2022
AGM 2021-11-12 2021

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue -- -- -- -- --
Other Revenue 1.235 M 1.107 M 1.679 M 939,771 1.058 M
Total Revenue 1.235 M 1.107 M 1.679 M 939,771 1.058 M
Interest Income 66,285 70,361 72,109 125,156 166,220
Interest Expenses -10,615 -4,190 -3,301 -2,200 0
Expenses -5.439 M -4.493 M -5.545 M -3.635 M -3.792 M
EBITDA -4.204 M -3.386 M -3.866 M -2.695 M -2.734 M
Depreciation and Amortization -474 -904 0 -1,471 0
Depreciation -474 -904 0 -1,471 0
Amortisation 0 0 0 0 0
EBIT -4.204 M -3.387 M -3.866 M -2.697 M -2.734 M
Pre Tax Profit -4.149 M -3.321 M -3.797 M -2.574 M -2.568 M
Tax Expense 0 0 0 0 0
Net Profit After Tax -4.149 M -3.321 M -3.797 M -2.574 M -2.568 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 0 0 0
Reported Net Profit After Abnormal Items -4.149 M -3.321 M -3.797 M -2.574 M -2.568 M
Ending Shares 641.053 M 394.261 M 394.261 M 215.726 M 215.1 M
Weighted Average Shares 611.805 M 394.261 M 244.545 M 215.222 M 213.785 M
EPS After Abnormal Items (cents) -0.68 -0.84 -1.55 -1.2 -1.2
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 17.598 M 8.705 M 11.639 M 6.622 M 8.861 M
Total Non Current Assets 3.369 M 3.367 M 3.368 M 3.369 M 3.369 M
Total Assets 20.967 M 12.072 M 15.007 M 9.991 M 12.23 M
Total Current Liabilities 514,675 864,244 668,030 543,775 440,646
Total Non Current Liabilities 25,002 19,707 17,763 7,785 4,249
Total Liabilities 539,677 883,951 685,793 551,560 444,895
Net Assets 20.427 M 11.188 M 14.321 M 9.439 M 11.785 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash -3.97 M -2.317 M -4.195 M -2.149 M -3.278 M
Net Invested Cash -2,314 0 0 -1,522 -21,686
Net Financing Cash Flows 12.75 M 0 8.367 M -635 1.221 M
Beginning Cash 7.357 M 9.64 M 5.486 M 7.645 M 9.754 M
End Cash Position 16.098 M 7.357 M 9.64 M 5.486 M 7.645 M
Exchange Rate Adjustments -36,945 34,623 -17,478 -8,203 -28,921
Other Cash Adjustments 0 0 0 0 0
Ending Cash 16.098 M 7.357 M 9.64 M 5.486 M 7.645 M

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK